{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T15:10:50Z","timestamp":1775920250822,"version":"3.50.1"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1097\/jcp.0b013e31827b9351","type":"journal-article","created":{"date-parts":[[2012,12,31]],"date-time":"2012-12-31T12:27:12Z","timestamp":1356956832000},"page":"95-98","source":"Crossref","is-referenced-by-count":9,"title":["Adjunctive Pregabalin in Partial Responders With Major Depressive Disorder and Residual Anxiety"],"prefix":"10.1097","volume":"33","author":[{"given":"Mario","family":"Vitali","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrico","family":"Tedeschini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martino","family":"Mistretta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiki","family":"Fehling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franca","family":"Aceti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauro","family":"Ceccanti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Fava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-18-20210128","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1192\/bjp.bp.108.054866","article-title":". Levels of anxiety and depression as predictors of mortality: the HUNT study.","volume":"195","author":"Mykletun","year":"2009","journal-title":"Br J Psychiatry"},{"key":"R2-18-20210128","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1007\/s11920-004-0007-y","article-title":"Increased mortality in depressive disorders: a review.","volume":"6","author":"Cuijpers","year":"2004","journal-title":"Curr Psychiatry Rep"},{"key":"R3-18-20210128","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1001\/archpsyc.57.4.375","article-title":". Psychosocial disability during the long-term course of unipolar major depressive disorder.","volume":"57","author":"Judd","year":"2000","journal-title":"Arch Gen Psychiatry"},{"key":"R4-18-20210128","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0193-953X(02)00107-7","article-title":". Background and rationale for the sequenced treatment alternatives to relieve depression (STARD) study.","volume":"26","author":"Fava","year":"2003","journal-title":"Psychiatr Clin North Am"},{"key":"R5-18-20210128","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0022-3956(96)00034-9","article-title":". Hostility changes following antidepressant treatment: relationship to stress and negative thinking.","volume":"30","author":"Fava","year":"1996","journal-title":"J Psychiatr Res"},{"key":"R6-18-20210128","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1177\/1359786806064325","article-title":"Pharmacological approaches to the treatment of residual symptoms.","volume":"20","author":"Fava","year":"2006","journal-title":"J Psychopharmacol"},{"key":"R7-18-20210128","first-page":"21","article-title":"Anger attacks in patients with depression.","volume":"60","author":"Fava","year":"1999","journal-title":"J Clin Psychiatry"},{"key":"R8-18-20210128","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0165-0327(97)00055-4","article-title":"The role and clinical significance of subsyndromal depressive symptoms (SSD) in unipolar major depressive disorder.","volume":"45","author":"Judd","year":"1997","journal-title":"J Affect Disord"},{"key":"R9-18-20210128","first-page":"4","article-title":"Augmentation and combination strategies in treatment-resistant depression.","volume":"62","author":"Fava","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"R10-18-20210128","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1176\/appi.ajp.2007.06111868","article-title":". Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STARD report.","volume":"165","author":"Fava","year":"2008","journal-title":"Am J Psychiatry"},{"key":"R11-18-20210128","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/da.20768","article-title":". Residual symptoms after remission of major depressive disorder with fluoxetine and risk of relapse.","volume":"28","author":"Iovieno","year":"2011","journal-title":"Depress Anxiety"},{"key":"R12-18-20210128","first-page":"181","article-title":"Vittengl SK, et al..","volume":"123","author":"Taylor","year":"2010","journal-title":"Which depressive symptoms remain after response to cognitive therapy of depression and predict relapse and recurrence J Affect Disord"},{"key":"R13-18-20210128","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jad.2007.01.020","article-title":". Residual symptoms and recurrence during maintenance treatment of late-life depression.","volume":"103","author":"Dombrovski","year":"2007","journal-title":"J Affect Disord"},{"key":"R14-18-20210128","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/01.pra.0000265772.26627.99","article-title":". Residual anxiety symptoms in depressed primary care patients.","volume":"13","author":"McIntyre","year":"2007","journal-title":"J Psychiatr Pract"},{"key":"R15-18-20210128","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jad.2004.11.007","article-title":"Treatment of residual anxiety symptoms with adjunctive aripiprazole in depressed patients taking selective serotonin reuptake inhibitors.","volume":"86","author":"Adson","year":"2005","journal-title":"J Affect Disord"},{"key":"R16-18-20210128","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.jpain.2008.03.013","article-title":". A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia.","volume":"9","author":"Arnold","year":"2008","journal-title":"J Pain"},{"key":"R17-18-20210128","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.pain.2008.02.027","article-title":". Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): a 6-month, double-blind, placebo-controlled trial with pregabalin.","volume":"136","author":"Crofford","year":"2008","journal-title":"Pain"},{"key":"R18-18-20210128","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1002\/art.20983","article-title":". Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial.","volume":"52","author":"Crofford","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R19-18-20210128","first-page":"502","article-title":". A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia.","volume":"35","author":"Mease","year":"2008","journal-title":"J Rheumatol"},{"key":"R20-18-20210128","first-page":"1319","article-title":". Anxiolytic-like effects of pregabalin.","volume":"25","author":"Kinsora","year":"1999","journal-title":"Abstracts of the Society for Neuroscience"},{"key":"R21-18-20210128","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/01.jcp.0000084032.22282.ff","article-title":". A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder.","volume":"23","author":"Feltner","year":"2003","journal-title":"J Clin Psychopharmacol"},{"key":"R22-18-20210128","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1176\/appi.ajp.160.3.533","article-title":". Pregabalin in generalized anxiety disorder: a placebo-controlled trial.","volume":"160","author":"Pande","year":"2003","journal-title":"Am J Psychiatry"},{"key":"R23-18-20210128","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/01.jcp.0000117423.05703.e7","article-title":". Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study.","volume":"24","author":"Pande","year":"2004","journal-title":"J Clin Psychopharmacol"},{"key":"R24-18-20210128","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1001\/archpsyc.62.9.1022","article-title":". Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam.","volume":"62","author":"Rickels","year":"2005","journal-title":"Arch Gen Psychiatry"},{"key":"R25-18-20210128","doi-asserted-by":"crossref","first-page":"771","DOI":"10.4088\/JCP.v67n0511","article-title":". Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine.","volume":"67","author":"Montgomery","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"R26-18-20210128","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.euroneuro.2008.01.004","article-title":". Efficacy of pregabalin in depressive symptoms associated with generalized anxiety disorder: a pooled analysis of 6 studies.","volume":"18","author":"Stein","year":"2008","journal-title":"Eur Neuropsychopharmacol"},{"key":"R27-18-20210128","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1177\/0269881107078496","article-title":"Pregabalin in the treatment of depression.","volume":"21","author":"Showraki","year":"2007","journal-title":"J Psychopharmacol"},{"key":"R28-18-20210128","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.pnpbp.2009.02.001","article-title":"Pregabalin augmentation to antidepressants in patients with major depressive disorder. Letter to the editor.","volume":"33","author":"Pae","year":"2009","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R29-18-20210128","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression.","volume":"23","author":"Hamilton","year":"1960","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JCP.0b013e31827b9351","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:00:42Z","timestamp":1620957642000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004714-201302000-00018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/jcp.0b013e31827b9351","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]}}}